BRIEF-Cassava Sciences Completes Interim Safety Review Of Oral Simufilam On-Going Phase 3 Trials

Reuters03-25

March 25 (Reuters) - Cassava Sciences Inc :

* CASSAVA SCIENCES ANNOUNCES COMPLETION OF AN INTERIM SAFETY REVIEW OF ORAL SIMUFILAM ON-GOING PHASE 3 TRIALS

* CASSAVA SCIENCES INC - FINAL CLINICAL SAFETY DATA FOR SIMUFILAM ARE EXPECTED AT CONCLUSION OF PHASE 3 PROGRAM

* CASSAVA SCIENCES INC - DSMB RECOMMENDED BOTH PHASE 3 TRIALS CONTINUE AS PLANNED, WITHOUT MODIFICATION

* CASSAVA SCIENCES INC - TOP-LINE RESULTS FOR 52-WEEK PHASE 3 TRIAL ARE CURRENTLY EXPECTED APPROXIMATELY YEAR-END 2024

* CASSAVA SCIENCES INC - TOP-LINE RESULTS FOR 76-WEEK PHASE 3 TRIAL ARE CURRENTLY EXPECTED APPROXIMATELY MID-YEAR 2025

Source text for Eikon: Further company coverage:

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2422517782?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-03-25 21:28","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2422517782","market":"us","top_or_hot":-1,"title":"BRIEF-Cassava Sciences Completes Interim Safety Review Of Oral Simufilam On-Going Phase 3 Trials","media":"Reuters","content":"<html><body><p>March 25 (Reuters) - <a href=\"https://laohu8.com/S/SAVA\">Cassava Sciences Inc</a>   :</p><p>   * CASSAVA SCIENCES ANNOUNCES COMPLETION OF AN INTERIM SAFETY REVIEW OF ORAL SIMUFILAM ON-GOING PHASE 3 TRIALS</p><p>   * CASSAVA SCIENCES INC - FINAL CLINICAL SAFETY DATA FOR SIMUFILAM ARE EXPECTED AT CONCLUSION OF PHASE 3 PROGRAM</p><p>   * CASSAVA SCIENCES INC - DSMB RECOMMENDED BOTH PHASE 3 TRIALS CONTINUE AS PLANNED, WITHOUT MODIFICATION</p><p>   * CASSAVA SCIENCES INC - TOP-LINE RESULTS FOR 52-WEEK PHASE 3 TRIAL ARE CURRENTLY EXPECTED APPROXIMATELY YEAR-END 2024</p><p>   * CASSAVA SCIENCES INC - TOP-LINE RESULTS FOR 76-WEEK PHASE 3 TRIAL ARE CURRENTLY EXPECTED APPROXIMATELY MID-YEAR 2025</p><p>Source text for Eikon:    Further company coverage:   </p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Cassava Sciences Completes Interim Safety Review Of Oral Simufilam On-Going Phase 3 Trials</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Cassava Sciences Completes Interim Safety Review Of Oral Simufilam On-Going Phase 3 Trials\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-03-25 21:28 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>March 25 (Reuters) - Cassava Sciences Inc   :   * CASSAVA SCIENCES ANNOUNCES COMPLETION OF AN INTERIM SAFETY REVIEW OF ORAL SIMUFILAM ON-GOING PHASE 3 TRIALS   * CASSAVA SCIENCES INC - FINAL CLINICAL ...</p>\n\n<a href=\"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4588","symbol_name":"碎股","start_time":0,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","article_id":"2422517782","we_media_id":"1036604489","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2422517782","pubTimestamp":1711373338,"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"summary":"March 25  - Cassava Sciences Inc   :   * CASSAVA SCIENCES ANNOUNCES COMPLETION OF AN INTERIM SAFETY REVIEW OF ORAL SIMUFILAM ON-GOING PHASE 3 TRIALS   * CASSAVA SCIENCES INC - FINAL CLINICAL SAFETY DATA FOR SIMUFILAM ARE EXPECTED AT CONCLUSION OF PHASE 3 PROGRAM   * CASSAVA SCIENCES INC - DSMB RECOMMENDED BOTH PHASE 3 TRIALS CONTINUE AS PLANNED, WITHOUT MODIFICATION   * CASSAVA SCIENCES INC - TOP-LINE RESULTS FOR 52-WEEK PHASE 3 TRIAL ARE CURRENTLY EXPECTED APPROXIMATELY YEAR-END 2024   * CASSAVA SCIENCES INC - TOP-LINE RESULTS FOR 76-WEEK PHASE 3 TRIAL ARE CURRENTLY EXPECTED APPROXIMATELY MID-YEAR 2025Source text for Eikon:    Further company coverage:    ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4588":"碎股","BK4007":"制药","BK4547":"WSB热门概念","BK4585":"ETF&股票定投概念","SAVA":"Cassava Sciences Inc"},"translate_title":"简介——Cassava Sciences完成正在进行的口服西莫非仑3期试验的中期安全性审查","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SAVA":0.9},"content_text":"March 25 (Reuters) - Cassava Sciences Inc   :   * CASSAVA SCIENCES ANNOUNCES COMPLETION OF AN INTERIM SAFETY REVIEW OF ORAL SIMUFILAM ON-GOING PHASE 3 TRIALS   * CASSAVA SCIENCES INC - FINAL CLINICAL SAFETY DATA FOR SIMUFILAM ARE EXPECTED AT CONCLUSION OF PHASE 3 PROGRAM   * CASSAVA SCIENCES INC - DSMB RECOMMENDED BOTH PHASE 3 TRIALS CONTINUE AS PLANNED, WITHOUT MODIFICATION   * CASSAVA SCIENCES INC - TOP-LINE RESULTS FOR 52-WEEK PHASE 3 TRIAL ARE CURRENTLY EXPECTED APPROXIMATELY YEAR-END 2024   * CASSAVA SCIENCES INC - TOP-LINE RESULTS FOR 76-WEEK PHASE 3 TRIAL ARE CURRENTLY EXPECTED APPROXIMATELY MID-YEAR 2025Source text for Eikon:    Further company coverage:    ((Reuters.Briefs@thomsonreuters.com;))","kind":null,"is_publish_news":null,"is_publish_highlight":null,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":1,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2422517782"}